leisure time -WSS

leisure time

author：explore 2025-09-30 01:01:11 - browse：961

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

focus

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

CRISPR gene editing developments we’re watching in 2024

SEC charges former device maker CEO with $41 million fraud

Albert Bourla of Pfizer: worst biopharma CEO of 2023

David Ricks of Eli Lilly: best biopharma CEO of 2023

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

entertainment

leisure time

knowledge

What does generative AI mean for health care? We asked experts

Health and fitness trackers are measuring the wrong things

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage beneficiaries sue Humana over algorithm use

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why health records don't always know when patients are dead

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As JPM 2024 winds down, some health tech firms project optimism

How to save PrEP access — and even expand it

Heart disease and mental health: A look at cardiac psychology

hotspot

Violet CEO on training clinicians to promote more inclusive care

The nurse manager staffing crisis is hurting patients

HCA sued by state AG for quality issues at Mission Health

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Prime Medicine, Myeloid Therapeutics clash over genome

Doulas covered by Medicaid under New York's new plan

knowledge

focus

entertainment

focus